Hjem › Hypofarynxcancer
Kliniske studier for Hypofarynxcancer rekrutterer i USA
19 studier for Hypofarynxcancer rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Atlanta, GA6 studier
- Chicago, IL6 studier
- Stevens Point, WI5 studier
- Joliet, IL5 studier
- Peoria, IL5 studier
- Bloomington, IL5 studier
- Wausau, WI5 studier
- Richmond, VA5 studier
- Cape Girardeau, MO5 studier
- Milwaukee, WI5 studier
- Kansas City, MO5 studier
- New York City, NY4 studier
- Edison, NJ4 studier
- Queens, NY4 studier
- Waukegan, IL4 studier
- Green Bay, WI4 studier
- Cedar Rapids, IA4 studier
- Evanston, IL4 studier
- Danville, IL4 studier
- Fargo, ND4 studier
- Lansing, MI4 studier
- Omaha, NE4 studier
- Champaign, IL4 studier
- Decatur, IL4 studier
- Aurora, IL4 studier
- St. Louis, MO4 studier
- Galesburg, IL4 studier
- Naperville, IL4 studier
- Flint, MI4 studier
- Oklahoma City, OK4 studier
- Charleston, IL4 studier
- Cicero, IL4 studier
- North Peoria, IL4 studier
- Waterford, MI4 studier
- Bozeman, MT4 studier
- Duluth, MN4 studier
- Pittsburgh, PA4 studier
- Baltimore, MD4 studier
- Cincinnati, OH4 studier
- Louisville, KY4 studier
Etter delstat
- Arizona3 studier
- Arkansas4 studier
- California7 studier
- Colorado6 studier
- Florida8 studier
- Georgia6 studier
- Idaho3 studier
- Illinois7 studier
- Indiana4 studier
- Iowa6 studier
- Kansas6 studier
- Kentucky4 studier
- Maryland5 studier
- Massachusetts5 studier
- Michigan5 studier
- Minnesota6 studier
- Missouri6 studier
- Montana4 studier
- Nebraska4 studier
- New Jersey4 studier
- New York8 studier
- North Carolina5 studier
- North Dakota4 studier
- Ohio8 studier
- Oklahoma4 studier
- Oregon3 studier
- Pennsylvania6 studier
- South Dakota3 studier
- Texas3 studier
- Virginia5 studier
- Wisconsin6 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06589804Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06997068BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05136196Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05172245Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT02734537Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07156227Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT07441681Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT04198766Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jul. 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT01365169Integrated Cancer Repository for Cancer Research
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 19 til 110 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT02012699Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 15. apr. 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 4. mar. 2026 · NCT06868433A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 19. feb. 2026 · NCT07063212Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. feb. 2026 · NCT06636734Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 10. feb. 2026 · NCT01473784Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RekruttererTidlig fase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. okt. 2025 · NCT06914999Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RekruttererObservasjonsstudie
Alder 21 til 90 · Alle kjønn · Oppdatert 22. sep. 2025 · NCT00900419Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.